AstraZeneca: Clinical Trials

606 completed. 606 Phase 2, 48 Phase 1, 35 Phase 3.

By phase and status

Phase	Trials	Status
Phase 2	606	Completed 606
Phase 1	48	Completed 48
Phase 3	35	Completed 35

Follow AstraZeneca: new trials by email

Trials (filtered) newest first · largest first

All 606 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Study to Investigate the Effect of AZD0780 Tablets in Combination With Rosuvastatin Tablets on Low Density Lipoprotein Cholesterol Levels (LDL-C) in Adult Participants With Dyslipidaemia Placebo, AZD0780, Rosuvastatin - Dyslipidaemia	Phase 2	Completed	AstraZeneca	76	2025-11-13	2026-10-14
A Study to Investigate Efficacy and Safety of Tozorakimab Injections Compared With Placebo in Adult Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations and Elevated Eosinophils Placebo, Tozorakimab - Chronic Obstructive Pulmonary Disease (COPD)	Phase 2	Completed	AstraZeneca	98	2025-04-12	2026-07-14
Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist AZD6234, Placebo to match - Endocrinology, Diabetes, Type II	Phase 2	Completed	AstraZeneca	69	2025-03-12	2026-09-24
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone AZD9550, AZD6234, Placebo comparator - Obesity or Overweight	Phase 2	Completed	AstraZeneca	377	2025-02-18	2026-06-03
A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI - Asthma	Phase 2	Completed	AstraZeneca	118	2025-02-10	2026-08-27
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis. AZD2389 - Liver Fibrosis, Hepatic Cirrhosis	Phase 2	Completed	AstraZeneca	40	2024-12-06	2026-07-06
A Study to Assess the Effect of AZD0780 on Ambulatory Blood Pressure Placebo, AZD0780 - Atherosclerotic Cardiovascular Disease	Phase 2	Completed	AstraZeneca	202	2024-10-30	2026-02-18
Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity AZD5004, Placebo - Obesity or Overweight	Phase 2	Completed	AstraZeneca	310	2024-10-08	2025-12-18
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus. Placebo (placebo matching AZD5004 film-coated tablet), AZD5004, Semaglutide - Diabetes Mellitus, Type 2	Phase 2	Completed	AstraZeneca	406	2024-10-08	2026-01-13
A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity AZD6234, Placebo comparator - Obesity or Overweight	Phase 2	Completed	AstraZeneca	262	2024-10-01	2026-10-02
A Dose Range-Finding Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD8630 in Adults With Uncontrolled Asthma at Risk of Exacerbations AZD8630, Placebo, Inhaler - Asthma	Phase 2	Completed	AstraZeneca	537	2024-08-30	2026-03-02
Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma AZD4604, Placebo to AZD4604 - Asthma	Phase 2	Completed	AstraZeneca	36	2024-08-05	2025-10-23
Anifrolumab for Hidradenitis Suppurativa Anifrolumab - Hidradenitis Suppurativa, Acne Inversa	Phase 2	Completed	University of North Carolina, Chapel Hill	15	2024-06-21	2026-08-03
A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension Baxdrostat, Placebo - Uncontrolled Hypertension	Phase 2	Completed	AstraZeneca	48	2024-06-10	2025-12-17
A Phase IIb Study of AZD5462 in Patients With Chronic Heart Failure AZD5462, Placebo - Chronic Heart Failure	Phase 2	Completed	AstraZeneca	375	2024-06-04	2026-07-08
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease Balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg, Balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg, Dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin - Chronic Kidney Disease	Phase 2	Completed	AstraZeneca	324	2024-05-01	2026-06-26
A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet), Zibotentan + placebo (placebo matching dapagliflozin tablet), Zibotentan + dapagliflozin - Liver Cirrhosis	Phase 2	Completed	AstraZeneca	73	2024-02-15	2026-01-20
Study of AZD9829 in CD123+ Hematological Malignancies AZD9829 - Hematological Malignancies	Phase 1 / Phase 2	Completed	AstraZeneca	56	2024-01-31	2026-07-01
A Study to Assess the Efficacy, Safety and Tolerability of Different Doses of AZD0780 in Patients With Dyslipidemia AZD0780, Placebo - Dyslipidemia	Phase 2	Completed	AstraZeneca	428	2024-01-19	2025-11-17
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA AZD4604, Placebo - Asthma	Phase 2	Completed	AstraZeneca	339	2023-11-16	2025-11-13

Showing 20 of 606. Sign in to see all of them.

Conditions studied

Breast Neoplasms (47)  ·  Pulmonary Disease, Chronic Obstructive (42)  ·  Carcinoma, Non-Small-Cell Lung (41)  ·  Diabetes Mellitus, Type 2 (41)  ·  Asthma (28)  ·  Lung Neoplasms (22)  ·  Neoplasms (21)  ·  Prostatic Neoplasms (21)  ·  Ovarian Neoplasms (19)  ·  Colorectal Neoplasms (18)  ·  Head and Neck Neoplasms (16)  ·  Neoplasm Metastasis (16)  ·  Obesity (16)  ·  Renal Insufficiency, Chronic (15)  ·  Diabetes Mellitus (14)

Interventions

durvalumab (66)  ·  Gefitinib (54)  ·  tremelimumab (33)  ·  olaparib (32)  ·  dapagliflozin (25)  ·  Fulvestrant (20)  ·  Anastrozole (18)  ·  Docetaxel (16)  ·  Cisplatin (15)  ·  Formoterol Fumarate (15)  ·  Paclitaxel (15)  ·  osimertinib (15)  ·  Carboplatin (14)  ·  cediranib (14)  ·  AZD 6244 (13)

Countries

United States (314)  ·  United Kingdom (131)  ·  Germany (111)  ·  Canada (103)  ·  Spain (99)  ·  France (87)  ·  Poland (74)  ·  Italy (66)  ·  Japan (61)  ·  Denmark (55)  ·  Hungary (55)  ·  Sweden (54)  ·  South Korea (53)  ·  Netherlands (51)  ·  Czechia (50)

Top investigators

Lisa Porter, MD (9)  ·  Esther Garcia, MD (7)  ·  Jane Robertson, BSc, MBCHB, MD (5)  ·  Bror Jonzon (4)  ·  James Malone, MD (4)  ·  Jane Robertson (4)

Results publications

PMID 26961146, PMID 19238149, PMID 23922302, PMID 26589105, PMID 26894924, PMID 34510411, PMID 35170751, PMID 17705687, PMID 18753666, PMID 21079055, PMID 22212857, PMID 22236356, PMID 22795280, PMID 23001587, PMID 23831734, PMID 24126931, PMID 24432712, PMID 25287629, PMID 25660356, PMID 27461213, PMID 29293889, PMID 30512189, PMID 31345012, PMID 34089147, PMID 34383954, PMID 35713300, PMID 37490693, PMID 38018702, PMID 38504437, PMID 38770818, PMID 39695768, PMID 40311309, PMID 40461100, PMID 42208007, PMID 16179100, PMID 16204015, PMID 17166340, PMID 17296644, PMID 17298834, PMID 17563856, PMID 17595353, PMID 17985985, PMID 18018771, PMID 18300255, PMID 18394265, PMID 18452610, PMID 18621625, PMID 18779612, PMID 18972276, PMID 19042080

NIH funding

2017 (11), 2016 (9), 2019 (9), 2023 (9), 2014 (8), 2015 (7), 2008 (5), 2018 (3), 2005 (2), 2009 (2), P30CA006516 (2), 1UH3TR001372-01 (1), 2004 (1), P30CA015704 (1), P30CA060553 (1)